




RealRate

PHARMACEUTICAL 2023

IntelGenx Technologies Corp. Rank 381 of 446





RealRate

PHARMACEUTICAL 2023

IntelGenx Technologies Corp. Rank 381 of 446



The relative strengths and weaknesses of IntelGenx Technologies Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IntelGenx Technologies Corp. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 107% points. The greatest weakness of IntelGenx Technologies Corp. is the variable Assets, Current, reducing the Economic Capital Ratio by 133% points.

The company's Economic Capital Ratio, given in the ranking table, is -156%, being 199% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	3,788
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,374
Liabilities, Non-Current	425
Other Assets	977
Other Compr. Net Income	-863
Other Expenses	2,635
Other Liabilities	9,814
Other Net Income	-1,277
Other Revenues	950
Property and Equipment	4,425
Research and Development	3,031
Selling, General and Administrative Expense	4,697

Output Variable	Value in 1000 USD
Assets	9,190
Liabilities	12,613
Expenses	10,363
Revenues	950
Stockholders Equity	-3,423
Net Income	-10,690
Comprehensive Net Income	-11,122
Economic Capital Ratio	-156%